Understanding the Clinical Scenario
This question presents a patient at the
nadir period following
FOLFOX chemotherapy. The nadir, typically occurring 7–14 days after myelosuppressive chemotherapy, represents the point of lowest blood cell counts. The nurse must rapidly identify the finding that poses the most immediate threat to life, applying the nursing principle of prioritizing airway, breathing, and circulation, while also recognizing the critical risk of infection in an immunocompromised host.
Analysis of Assessment Findings
The core of this clinical decision is distinguishing between expected chemotherapy side effects and a life-threatening oncologic emergency.
Why Option 4 is the Priority
A
white blood cell count of
1,200/mm³ with an
absolute neutrophil count (ANC) of
480/mm³ defines
severe neutropenia. According to expert guidance, severe neutropenia is defined as a blood neutrophil count of less than
0.5 × 10⁹/L (equivalent to
500/mm³)
[1]. This level of immunosuppression means the patient has virtually no defense against bacterial and fungal pathogens. A simple infection can rapidly progress to sepsis and septic shock, making this the most time-sensitive and life-threatening finding. Chemotherapy-induced neutropenia (CIN) is the most common dose-limiting toxicity and is directly linked to life-threatening infections, treatment delays, and increased mortality
[2][3]. The immediate intervention required is the implementation of neutropenic precautions, notification of the provider, and likely initiation of broad-spectrum antibiotics and colony-stimulating factors.
Why Other Options are Lower Priority
-
Option 1: A temperature of
100.2°F (37.9°C) with mild fatigue is concerning in a neutropenic patient, but the question stem does not yet provide the ANC. On its own, a low-grade fever is not as immediately critical as a documented severe neutropenia. However, if this fever were present with the ANC in option 4, it would constitute a febrile neutropenia emergency.
-
Option 2: Numbness and tingling in fingertips when touching cold objects is a classic, pathognomonic sign of
oxaliplatin-induced peripheral neuropathy. This is an expected, non-life-threatening adverse effect of the FOLFOX regimen. It requires dose adjustment and symptom management but does not represent an immediate threat to survival.
-
Option 3: Nausea with decreased appetite and a weight loss of 2 pounds reflects a common gastrointestinal toxicity of 5-fluorouracil. While distressing and requiring nutritional and antiemetic support, this finding does not pose an immediate risk of mortality compared to severe neutropenia.
Clinical Decision-Making and Pathophysiology
The pathophysiologic basis for this priority is the myelosuppressive effect of the FOLFOX regimen, particularly from 5-fluorouracil. These agents target rapidly dividing cells, including hematopoietic stem cells in the bone marrow, leading to a predictable decline in neutrophils. The severity of CIN is a critical factor in patient outcomes, as it can lead to febrile neutropenia, a major cause of chemotherapy-related morbidity and mortality . A standardized management pathway is essential because the risk of overwhelming sepsis increases dramatically when the ANC falls below the severe threshold
[2]. The nurse's immediate recognition and response—isolating the patient, initiating a sepsis workup, and preparing for granulocyte colony-stimulating factor (G-CSF) administration—directly prevent clinical deterioration. The dynamic and often predictable nature of CIN across cycles means that this first-cycle nadir also provides crucial data for predicting and preventing future episodes with prophylactic measures
[3].
References (research sources)
- [1]
Diagnosis and management of neutropenia in adults: Expert guidance.Research articleWelte K, Zeidler C, Skokowa J, Mellor-Heineke S, Bolyard AA, Dale D. (2026) · DOI: 10.1111/bjh.70640
- [2]
Development and practice of a standardized management pathway for chemotherapy-induced neutropenia in patients with gynecological malignancies.Research articleDan X, Tian Y, Yin R, Song L, Li S, Chen L, Huang Y, He Y. (2026) · DOI: 10.1007/s00520-026-10841-5
- [3]
Dynamic evolution, prediction and patient stratification of chemotherapy-induced neutropenia in a predominantly breast cancer cohort: A decision-support study for building a bundle care strategy.Research articleDai S, Zhang X, Qiao Z, Li L, Ye L. (2026) · DOI: 10.36721/pjps.2026.39.10.282.1